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ABSTRACT
Fructose and simple sugars are a substantial part of the western diet, and their inﬂuence on human health remains controversial. Clinical studies
in fructose nutrition have proven very difﬁcult to conduct and interpret. NIH and USDA sponsored a workshop on 13–14 November 2012,
“Research Strategies for Fructose Metabolism,” to identify important scientific questions and parameters to be considered while designing clinical
studies. Research is needed to ascertain whether there is an obesogenic role for fructose-containing sugars via effects on eating behavior and
energy balance and whether there is a dose threshold beyond which these sugars promote progression toward diabetes and liver and
cardiovascular disease, especially in susceptible populations. Studies tend to fall into 2 categories, and design criteria for each are described.
Mechanistic studies are meant to validate observations made in animals or to elucidate the pathways of fructose metabolism in humans. These
highly controlled studies often compare the pure monosaccharides glucose and fructose. Other studies are focused on clinically significant
disease outcomes or health behaviors attributable to amounts of fructose-containing sugars typically found in the American diet. These are
designed to test hypotheses generated from short-term mechanistic or epidemiologic studies and provide data for health policy. Discussion
brought out the opinion that, althoughmany mechanistic questions concerning the metabolism of monosaccharide sugars in humans remain to
be addressed experimentally in small highly controlled studies, health outcomes research meant to inform health policy should use large, long-
term studies using combinations of sugars found in the typical American diet rather than pure fructose or glucose. Adv. Nutr. 5: 248–259, 2014.
Introduction
In response to public, industry, and academic interest in the
health effects of fructose and other simple sugars, the Na-
tional Institute of Diabetes and Digestive and Kidney Dis-
eases, the National Heart Lung and Blood Institute, and
the USDA supported a workshop on 13–14 November 2012
entitled “Clinical Research Strategies for Fructose Metabo-
lism” (1). Despite substantial ongoing research, it has been
difficult to reach consensus regarding the roles played by fruc-
tose and other simple sugars in the recent rise in obesity and
related metabolic diseases. Therefore, the main objective of
this workshop was to identify the most important unan-
swered questions concerning dietary fructose and other sug-
ars and explore optimal designs in clinical research to answer
these questions. The workshop was chaired by Drs. John
Bantle, Peter Havel, and Elizabeth Parks and was attended
by >100 participants from academia, government, advocacy
groups, and industry.
Fructose is a simple sugar that exists as a natural constit-
uent of foods, in either free form or a 1:1 combination with
glucose as the disaccharide sucrose. Fructose-containing
sugars (FCSs)8 include sucrose, high fructose corn syrup
(HFCS; 42–55% fructose), honey, fruit juice concentrates,
agave nectar, and crystalline fructose. Starting in the 1970s,
there was both an increase in overall sugar consump-
tion in the United States and a number of other countries
and a replacement of sucrose with HFCS in beverages and
1 On behalf of the organizers and participants in a 2012 National Institutes of Health and
USDA-sponsored workshop, “Clinical Research Strategies for Fructose Metabolism.”
Funding for the workshop was from the National Institute of Diabetes and Digestive and
Kidney Diseases, the National Heart Lung and Blood Institute, and the USDA.
2 Author disclosures: E. Parks serves on the Atkins Nutritionals Scientific Advisory Board,
Merck Speakers Bureau and receives funding from Merck. M. R. Laughlin, J. P. Bantle,
P. J. Havel, D. M. Klurfeld, K. Teff, P. Maruvada, no conflicts of interest.
* To whom correspondence should be addressed. E-mail: maren.laughlin@nih.gov.
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other processed foods (2). Although the consumption of
HFCS rose at approximately the same time as the increase
in obesity and diabetes (3), no clear association between
consumption of fructose in any form and metabolic conse-
quences has been demonstrated conclusively in the absence
of overeating and weight gain (4–6). In fact, the per capita
availability of total added sugars in the United States had
declined 13.7% by 2011 from a peak in 1999, and ~80%
of that decline was from reduced HFCS (7), whereas rates
of overweight among adults aged $20 y have continued
to increase from 65.2% in 1999–2002 to 68.5% in 2007–
2010, and diabetes rose from 9.8% to 11.4% in the same
timeframe (8).
Studies of the fate of fructose in cells and animal models
have also drawn attention to this molecule as a possible trig-
ger for obesity and metabolic syndrome (9,10), and the ul-
timate goal of the clinical studies that use a fructose-rich
diet intervention is to determine whether the metabolic
pathways and health effects noted in animal models also oc-
cur in humans. Typically, however, animals are fed high
doses of pure fructose or other sugars to elicit health-related
outcomes [for instance, 60% of calories are derived from
fructose for the fructose-fed rat model (10)]. Much of the
mechanistic research performed on humans also compares
substantial doses (for example, 25% of estimated total ca-
loric need) of pure fructose with glucose. Humans normally
ingest FCS rather than pure fructose, in variable doses and
in combination with a variety of other foods. Therefore, re-
search is still critically needed to understand whether fruc-
tose, in the doses and forms typically consumed, poses
health risks to the American people.
Although similar to glucose in caloric yield, fructose is
metabolized quite differently. Glucose is obtained from sim-
ple sugars and complex carbohydrates in the diet, is also pro-
duced endogenously, and is metabolized by virtually all cells
and organs in the body. There are a multitude of regulatory
systems that function to maintain blood glucose within tight
limits, because both hyperglycemia and hypoglycemia have
pathologic consequences. Therefore, extra glucose in the
diet may provide unneeded calories but is likely metabolized
along its normal highly regulated pathways. Fructose is al-
most exclusively derived from the diet. It is quickly removed
from the circulation primarily by the liver in which a sizable
fraction is converted to glucose. It promotes the synthesis
and storage of glycogen and TG in the fed state (9). Animals
fed large doses of fructose [rats at 60% of energy (10), mon-
keys supplemented with 75 g/d fructose (11)] gained consid-
erable adipose tissue and exhibit many of the hallmarks of
metabolic syndrome (12). Fructose, unlike glucose, is not
associated with the postprandial rise in glucose and insulin
secretion or diurnal leptin production that is regulated by
insulin and glucose and that together contribute to short-
term satiety and the long-term regulation of energy homeosta-
sis (13). This raises the question of whether dietary fructose
promotes overeating. These and similar observations form
the basis for a focus on the human health effects of fructose
and the fructose component of FCS.
The workshop was organized in 4 scientiﬁc sessions with
ample time for discussion: 1) an overview of fructose metab-
olism; 2) its effect on energy balance; 3) the effect of fructose
feeding studies in humans and nonhuman primates; and 4)
the effect of fructose consumption on renal and hepatic me-
tabolism and function. During a final session, hypothetical
clinical study designs were presented for discussion. This ex-
ercise allowed participants to discuss best practices in proto-
col design for interventional clinical studies of the health
and metabolic effects of fructose and simple sugars. The fol-
lowing brief description of the presentations and discussions
is organized by science rather than by session. There are out-
standing recent reviews of fructose metabolism and its role
in human disease (14–16), and the current report will not
attempt to improve on these. Rather, the emphasis here
will be on novel information and dominant themes from
the workshop presentations and discussions that inform
clinical trial design.
Workshop Summary
Fructose and its metabolism
In 2004, sugar consumption in the United States was ~18%
of energy in the typical U.S. diet. A total of 42% of this sugar
was consumed as HFCS, which is a mixture of the monosac-
charides glucose, fructose, and other sugars, 44% was in the
form of sucrose, and other sugars, such as lactose and the
free fructose and glucose in fruit, made up the balance (2).
The contribution made by HFCS has been falling since
approximately 1999, and the most recent data compiled by
the USDA for 2011 show that HFCS now comprises ~36%
of total added sugars in the food supply, whereas sucrose
contributes ~51% (7). Regardless of the form, approxi-
mately half of all dietary sugar is fructose, and it is never
consumed as the only sugar in a normal diet.
Bernadette Marriott analyzed 1999–2004 NHANES data
to estimate mean fructose consumption, which varies by
gender and age. On average, Americans consumed 49 g/d
fructose (187 kcal/d), which is 9.4% of a 2000 kcal/d diet.
On the low end, women aged >51 y consumed 32 g/d
(8.0% of energy intake), whereas boys aged 15–22 y were
the highest consumers at 75 g/d. American boys and girls
this age thus consume on average 11–12% of their energy
as fructose, and those at the 95th percentile of mean intake
get 16.0–17.9% of their daily energy from fructose (2). Be-
cause fructose makes up approximately half of all sugars,
these numbers must be doubled to describe U.S. sugar con-
sumption. This is well above the AHA recommendation
limiting all added sugars to 100 kcal/d (26.2 g/d) for women
and 150 (39.3 g/d) for men (17), or the Health and Human
Services/USDA Dietary Guidelines for Americans 2010,
which, rather than addressing dietary sugars in isolation,
recommend a combined limit for solid fats and added sugars
of 5–15% of total calories (18).
The metabolic pathways and extremes of the phenotypes
associated with high fructose diets have been investigated
in animal models. Andrew Bremer presented the results
of studies in which healthy middle-aged rhesus macaques
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were fed, in addition to an ad libitum diet, a large daily dose
of fructose (75 g/d, ~30% of ingested calories) for 1 y. Al-
though total daily calorie intake was increased by only ~3%
during fructose feeding, all monkeys exhibited increases of
body weight and adiposity, insulin resistance, dyslipidemia,
and increased circulating inﬂammatory markers, and 4 of
29 animals developed overt type 2 diabetes (11). Richard
Johnson presented data on the metabolic pathways of acute
and chronic fructose metabolism in rodent and cell models.
Fructose rapidly enters the liver, one-third to one-half is
converted to glucose, and it facilitates glucose uptake, as
well. The sugars are oxidized, released as lactate, stored as
glycogen, or converted into lipid to be stored in adipose or
liver. Fructose is metabolized so quickly that, in rats fed
60% of calories as fructose, it can cause elevated plasma
uric acid, possibly via a transient reduction in liver ATP
and subsequent additional breakdown of adenine nucleo-
tides. Uric acid has lipogenic effects at high concentrations
(10,12,19,20). Chronic fructose or sucrose feeding induces
proteins associated with fructose transport (glucose trans-
porter 5) and metabolism (fructokinase, carbohydrate re-
sponse element binding protein, sterol regulatory element
binding protein-1c, peroxisome proliferator-activated re-
ceptor g coactivator-1, and FA synthase) in rodents, further
stimulating fructose disposal and potential side effects of
obesity, inflammation, fatty liver, insulin resistance, hy-
pertriglyceridemia, hypertension, and kidney disease
(12,14,21).
These and similar observations in animal models and
cells exposed to substantial doses of fructose underlie con-
cern about the health effects of the typical amounts of die-
tary fructose in humans, but clinical studies have been
difﬁcult to conduct and interpret, and experimental evi-
dence for these effects are controversial. John Sievenpiper
reported the results of a series of meta-analyses of >50 small,
short clinical studies of high daily fructose ingestion that
used a variety of protocols on different populations. Fruc-
tose doses ranged from well below the typical U.S. diet
(22.5 g/d, or 4.5% of required energy) to well above (300
g/d, equal to 55% of required energy) (4). Together, they
show no consistent effect of fructose on important health
outcomes, such as weight gain, hyperlipidemia, hyperten-
sion, hyperglycemia, and liver fat when individuals were
constrained to a defined weight-maintenance diet. However,
if sugar-sweetened beverages are added to an ad libitum diet,
individuals often, but not always, fail to reduce food intake
to compensate for the excess calories in the sweetened bev-
erages, and they gain weight. Under these circumstances,
many of the markers of metabolic syndrome (fatty liver, in-
sulin resistance, TGs, uric acid) are clearly elevated with high
fructose diets (4–6). It is not clear which effects are caused
by fructose per se, the state of positive energy balance, or
as a consequence of synergy between the 2. This is a funda-
mentally important question regarding the metabolic effects
of dietary FCS that can only be addressed with new carefully
controlled clinical studies. Furthermore, the measured out-
comes of fructose feeding studies are highly dependent
on study design. Meta-analysis is useful in that it can iden-
tify strong signals from a series of small studies but can
also suppress the real outcomes of individual studies. Data
interpretation is further complicated by the highly variable
ability of individuals to absorb dietary fructose from the
gut, which is rarely measured but which is affected by previ-
ous history of fructose ingestion, ethnicity, gender, obesity,
and other dietary components (22,23). Therefore, these
parameters likely affect the outcome of clinical research
focused on the health effects of fructose. John Sievenpiper
repeatedly called for additional larger, longer, well-designed
studies.
Fructose effects on energy balance and ingestive
behavior
Animals tend to accumulate fat on high fructose diets
(10,11), and FCS consumption in the United States corre-
lated with obesity over time until approximately 2000 in
human population studies (7,8). But does fructose per se
contribute to weight gain? If so, it must either reduce energy
expenditure or increase food intake. Luc Tappy, Nancy
Keim, Jonathan Purnell, and Sonia Caprio addressed this
question by presenting data from studies of energy balance
in individuals consuming fructose and by monitoring inges-
tive behavior or using brain imaging approaches after a fruc-
tose challenge. Ten weeks of fructose ingestion at 25% of
the total energy requirement established at study baseline
reduced resting metabolic rate relative to a diet with the
same glucose dose in obese, insulin-resistant middle-aged
individuals, but a similar amount of fructose for 4 wk
(18% of total energy requirements) did not alter energy ex-
penditure in lean individuals (24,25). In fact, a fructose meal
increased postprandial thermogenesis relative to glucose in
lean and obese individuals and those with diabetes, indicat-
ing that weight gain in response to fructose is not likely
initiated through reduced energy expenditure (26–28). Do
fructose calories go undetected by the brain and fail to
curb hunger? There are currently only limited data available
that can address this question. Intracerebroventricular infu-
sion of 400 mg of glucose into mice increases ATP in the hy-
pothalamus and reduces food intake on the following day,
but a similar load of fructose reduces hypothalamic ATP
and actually doubles subsequent food intake (29,30). How
these results relate to ingestion of fructose, which is rapidly
cleared by the liver, remains speculative. After a meal, hun-
ger is curbed through the combined action of many neural
and circulating signals. However, fructose ingestion (30%
of total estimated energy needs) did not elicit the large post-
prandial excursion of the satiety hormone insulin seen in
normal-weight women after a glucose meal, the typical diur-
nal rise in plasma leptin was reduced, and the orexogenic
hormone ghrelin was less suppressed (13). Therefore, a fruc-
tose preload may result in the subsequent ingestion of more
calories than a similar glucose preload as observed by some
researchers (31). However, others observed that individuals
eat less after a fructose than glucose challenge (32), and still
others reported similar weight gain on high fructose and
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glucose diets (33). It must be noted that studies of food in-
take in humans are notoriously difficult to conduct. Individ-
uals do not always eat naturally when under observation in
the laboratory environment, other meal components, such
as starch, may affect hunger, and studies in free living indi-
viduals rely on inadequate measures (questionnaires, food
diaries) to detect small changes in a complex behavior.
Despite conﬂicting physiologic and behavioral data re-
garding the energy balance effects of fructose and glucose,
imaging studies show differences in the response to i.v. infu-
sion of 0.3 mg/kg of these 2 sugars in brain fMRI activation
patterns (34) and in cerebral blood ﬂow after ingestion of
75 g of sugar (35). It is difﬁcult to control these studies for
all the factors that affect the brain response to food, such as
sensory perception (taste, smell, mouth feel, visual cues),
circulating nutrients and hormones, memories, and emo-
tional responses. Therefore, imaging data cannot always be
interpreted in a straightforward way. However difﬁcult it
has been to demonstrate a single mechanism whereby fruc-
tose directly causes weight gain in humans, there do appear
to be detectable phenomena in the brain and periphery that
may be involved, and new tools and experiments are needed
for additional investigation to better understand the rele-
vance of brain activity to eating behaviors. These observa-
tions should inform design of future metabolic studies, as
well; overfeeding studies that add sugar supplements to an
ad libitum diet often result in a hypercaloric diet, and a pos-
itive energy status clearly conveys adverse health effects in
the absence of high sugars. However, if humans routinely
fail to compensate for added FCS as a result of fructose effects
on satiety pathways, this experimental paradigm more faith-
fully represents the normal U.S. diet than those constrained
to energy balance. A more complete understanding of the
role of dietary sugars in brain responses and eating behavior
will require the use of complex meals that contain both glu-
cose and fructose.
Fructose effects on lipid metabolism
Elizabeth Parks reported that fructose, especially when ab-
sorbed quickly in liquid form, stimulates the de novo syn-
thesis of lipid in the human liver. Stimulation of de novo
lipogenesis has both quantitative and qualitative implica-
tions—upregulation of this pathway elevates intracellular
malonyl-CoA, which increases the re-esterification of die-
tary fat (36,37), the FAs synthesized significantly contribute
to liver TG stores (38) and to VLDL TG synthesis (39–41),
and the primary products of de novo lipogenesis are satu-
rated FAs that can have negative effects on cellular metabolic
functions, such as insulin signaling (42). Fructose and glu-
cose are highly synergistic; glucose facilitates intestinal ab-
sorption of fructose (22), and fructose stimulates glucose
uptake into the liver (43,44). Inclusion of fructose with an
oral glucose load stimulates lipogenesis 4-fold relative to
glucose alone (36). In the presence of obesity, non-alcoholic
fatty liver disease (NAFLD), and insulin resistance, lipo-
genesis is further elevated with a loss of circadian modula-
tion that results in continuous lipid production (38). TG
clearance and lipid oxidation are suppressed (23,45), leading
to a substantial increase in total and saturated LDLTGs over
that seen with glucose or complex carbohydrates (46,47).
After 10 wk of ad libitum diet including 25% of energy
from a single monosaccharide sugar, Kimber Stanhope ob-
served that obese insulin-resistant adults fed fructose had
signiﬁcantly increased de novo lipogenesis, increased vis-
ceral adiposity, reduced insulin sensitivity, elevated post-
prandial TGs, increases of lipid risk factors, including
LDL-cholesterol, small-dense LDL, and remnant lipopro-
teins, reduced fat oxidation, and increased carbohydrate ox-
idation relative to those fed the same amount of glucose,
despite similarly increased calorie intake and weight gain
(23,33). The same group showed that effects can occur
very quickly and be independent of positive energy balance.
LDL-cholesterol and apo-B were increased after only 2 wk
of either HFCS or pure fructose consumed at 25% of en-
ergy requirements in a group of individuals that included
both normal-weight and overweight/obese young men and
women but who did not experience signiﬁcant weight gain
(47). Jean-Marc Schwarz showed preliminary data in which
individuals fed a controlled diet for only 1 wk with 25% of
energy requirements derived from fructose appeared to
have an impaired metabolic phenotype relative to those on
an isocaloric complex carbohydrate diet (personal com-
munication from Jean-Marc Schwarz, Touro University,
Vallejo, CA).
Chronic hyperlipidemia (particularly in which saturated
lipids are elevated), visceral adiposity, and fatty liver are all
known risk factors for inﬂammation, insulin resistance,
and cardiovascular disease. Although still an important
open question that requires additional research, the presen-
tations discussed above (see Fructose effects on lipid meta-
bolism) raised the issue of whether long-term habitual
ingestion of FCSs, even in the absence of weight gain, can
lead to frank metabolic disease. Does the fructose-induced
dyslipidemia experienced by obese insulin-resistant individ-
uals make them more susceptible to diabetes and cardiovas-
cular disease? What are the threshold doses and modulating
factors? For instance, a protective role of physical activity
was demonstrated recently (48).
Increased intrahepatic TG in children
Miriam Vos and Michael Goran presented studies focused
on the role of fructose in obese children and adolescents
with NAFLD. In 2010, 10.7% of adolescents in the United
States had fatty liver, including almost half of all obese
boys, who are particularly susceptible (49). Fructose feeding
(33% of required energy for all 3 meals of 1 d) increased
24-h circulating TGs in all adolescents by almost 2-fold, but
plasma TG concentrations were higher and more variable
in those with fatty liver (1421 vs. 622 mg/dL) (50). Excess
weight gain can be reduced by avoiding sugar-sweetened
beverages for 18 mo in normal-weight children aged 5–12 y
(51). Michael Goran discussed the influence of ethnicity
and race. It was observed recently that, after 2 y, an inter-
vention to reduce intake of sugar-sweetened beverages in
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overweight and obese adolescents showed no differences in
weight gain overall, but analysis of the data by ethnicity
showed 10 kg less weight gain in Hispanic children com-
pared with untreated Hispanic children (52). Hispanic chil-
dren are more likely to have fatty liver and insulin resistance,
in part because of a high incidence of the patatin-like phos-
pholipase domain-containing protein 3 susceptibility gene
variant. African-American children rarely have this muta-
tion and have a much lower incidence of fatty liver, but
if they do develop fatty liver they are also more likely to be
insulin resistant and have diabetes, as well. It is interesting to
note that ~71% of African Americans experience fructose
malabsorption relative to only 43% of Hispanics (23). It is
not known whether this helps protect African Americans
from the metabolic consequences of a high FCS diet, espe-
cially because malabsorption may not be appreciable except
when fructose is ingested in the absence of other sugars and
nutrients (53,54).
These studies reveal that genetics, ethnicity, and gender
all likely interact with diet to produce the current high
amounts of obesity, NAFLD, and insulin resistance. Restric-
tion of sweetened drinks can have a measureable positive
effect, although the relative contributions from reduced
fructose, altered satiety, or simple calorie restriction have
not been investigated thoroughly. Because very early meta-
bolic disease is associated with lifelong health risks, it is im-
portant to identify and remediate the triggers of childhood
obesity and attendant complications.
Inﬂuence of fructose on adipose inﬂammation and
liver and kidney disease
This portion of the conference explored some of the mech-
anisms that may mediate the effects of fructose metabolism
on disease and organ dysfunction. Inﬂammation is recog-
nized to contribute to insulin resistance and is associated
with increased deposition of visceral adipose tissue, NAFLD,
and elevated saturated lipids, all of which are seen with both
high amounts of ingested fructose and obesity. To tease these
apart, Mario Kratz showed preliminary data from a cross-
over study in which individuals on an ad libitum diet drank
beverages providing 25% of their daily energy requirement
from glucose, fructose, or with the noncaloric sweetener as-
partame for 8 d. Treatment phases were separated by wash-
out periods. Glucose and fructose drinks resulted in similar
levels of overeating (15–19%), but circulating amounts of
the inflammatory markers C-reactive protein and interleu-
kin-6 were elevated only in individuals consuming fructose
(55) (personal communication from Mario Kratz, Fred
Hutchinson Cancer Research Center, Seattle, WA). A recent
paper found no increase in inflammatory markers in lean
young individuals with 4 wk of 150 g/d (575 kcal) fructose
or glucose consumption as part of a hypercaloric diet (56).
Manal Abdelmalek presented preliminary data indicating
that a fructose challenge might serve as a biomarker for liver
disease. The transient dip in liver ATP seen with 31P magnetic
resonance spectroscopy during infusion of 250 mg/kg body
weight fructose is blunted in non-alcoholic steatohepatitis,
and recovery of the ATP signal may be delayed as liver dis-
ease progresses and mitochondrial function is compromised
(57). Perhaps secondary to this disturbance in liver ATP, in-
gestion of high amounts of fructose is associated with ele-
vated uric acid in rodents (58) and humans (19). Miguel
Lanaspa reported the results of studies in rodents and cul-
tured cells showing how fructose, in part via the generation
of uric acid, provokes endothelial inflammation, hyper-
tension, and altered glomerular hemodynamics that may
ultimately underlie chronic kidney disease (59). He also
showed data that support the idea that fructose can be gen-
erated endogenously in the polyol pathway through the ac-
tion of aldose reductase and sorbitol dehydrogenase. Hepatic
and plasma fructose were elevated by 30–50% in mice fed an
unpurified diet after 14 wk, during which drinking water
was replaced with 10% glucose solution, and these changes,
as well as elevated liver TG, were abolished in mice that
lacked aldose reductase (60). It is not known whether fruc-
tose is produced endogenously in individuals eating a typical
diet.
In summary, the presentations and discussion at the
workshop indicated that high-quality studies to investigate
the effects of dietary fructose and FCS are still needed to un-
derstand whether the disease mechanisms postulated from
animal experiments are operational in humans. Many of
the studies designed to elucidate health and metabolic effects
used pure fructose at 25% or more of required energy as an
intervention, which rarely occurs in a normal diet. There-
fore, larger studies in susceptible populations using real-
world dietary interventions (for instance, sucrose or HFCS
within the range typically consumed in the United States)
would clarify whether dietary sugars play a role in disease
progression and inform the public concerning safe amounts
of dietary disaccharides or combinations of monosaccharides.
Panel Discussion: Commentary on Design of
Clinical Studies for Investigation of Fructose
Metabolism and the Health Effect of Sugars
in the Diet
Workshop participants submitted responses to the following
questions, and the answers are summarized in Tables 1–3.
In addition, 3 groups of attendees were asked to present hy-
pothetical study protocols in a last session led by Meredith
Hawkins. These hypothetical studies focused on at-risk pop-
ulations, such as obese children and adults with prediabetes,
and on the outstanding questions in Table 1. Important
points taken from discussion of these protocols are found
in Table 2: 1) what are the important outstanding questions
concerning fructose and human health that remain to be
answered? (Table 1); 2) what are important experimental
parameters and other design considerations for clinical stud-
ies? (Table 2); and 3) what are important outcomes variables
for clinical studies? (Table 3).
A few words are needed about some questions that were
raised but after discussion were considered inappropriate for
inclusion in Table 1. Although differences of opinion exist
(61), overall there was a sense that the considerable body
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of research comparing health effects of HFCS (45–55% fruc-
tose) with sucrose (50% fructose) had not shown large differ-
ences between these 2 sources of simple sugars. There was also
discussion regarding the usefulness of comparing diets rich in
pure fructose and glucose; because these pure monosaccharides
are not found in normal diets, studies focused on the health ef-
fects of sugar-rich diets should likely use sucrose, HFCS, or a
combination of glucose and fructose in other forms (i.e., fruit).
However, it remains important to understand differences in
how the human body handles the monosaccharides, and
such studies are included herein in the category of “mechanistic
studies” (Table 2). It was noted that glucose is abundant in
blood and produced rapidly from stored glycogen or ingested
carbohydrates and proteins and that the ratio of glucose/fruc-
tose in a typical diet is >3:1 (62). Therefore, it is unlikely that
fructose, evenwhen present as the only simple sugar in the diet,
is ever metabolized in the absence of glucose.
Table 3 lists the outcomes measures that workshop par-
ticipants judged to be most informative, divided into acute
measures of sugar and lipid metabolism, eating behavior
or brain activity, and behaviors and disease biomarkers that
may be altered by chronic changes in dietary sugar ingestion.
Although the techniques for making these measurements will
not be discussed in any detail, it is important to note that, to
be compared among groups and interpreted, some of them
may require a short preparatory period lasting $1 d, during
which diet and activity are controlled [such measures include
de novo lipogenesis and insulin resistance (33,36)]. The hydro-
gen breath test, although not entirely reliable, indicates that
30–80% of healthy individuals experience malabsorption, but
not necessarily symptoms, after large doses of ingested fructose
(25–50 g) in the absence of other nutrients (53,54). This
must be kept in mind. It should also be noted that the acute
response to a sugar challenge can be used to study a particular
pathway (such as the appearance of fructose carbons in newly
synthesized FAs) but can also serve as a disease biomarker
[such as the oral glucose tolerance test or the recovery rate of
liver ATP after fructose infusion (57)], and so care should be
taken to distinguish among the reasons for including outcomes
measures in the study design and to use only those that can be
interpreted in light of the hypothesis and design.
In general, designs for interventional clinical studies of
dietary sugars tend to fall into 2 categories: 1) small short
mechanistic studies designed to validate observations made
in animals, to elucidate the pathways of fructose metabolism
or influence of fructose on other pathways in humans; and
2) larger, longer studies focused on clinically significant dis-
ease outcomes or health behavior resulting from chronically
consumed diets, designed to test hypotheses generated from
short-term mechanistic studies in humans or epidemiologic
studies and to provide data for dietary recommendations
and health policy. The design criteria can be quite different
for these 2 types of studies. However, depending on the spe-
cific questions being posed, study designs can mix elements
of the 2, and care should be taken to ensure that outcomes
are interpretable in terms of either biologic mechanism or
the realm of public health.
Mechanistic Studies
Hypotheses
The hypothesis for small, short studies should be narrowly
framed and may be highly mechanistic (Table 1) but should
TABLE 1 Important questions regarding the metabolism and health effects of fructose-containing sugars1
Does fructose in the diet uniquely alter ingestive behavior or energy balance and therefore initiate or worsen obesity?
Does fructose affect satiety after a meal differently than other nutrients?
Does the state of obesity alter the influence of fructose on satiety and energy homeostasis?
Are brain chemistry and function changed by chronic consumption of FCS? Which regions and pathways are involved—the reward systems, regions
that control energy homeostasis?
Is the energy of FCS consumed in beverages sensed differently by the body than sweetened solid food, and does that affect satiety and ingestive
behavior?
Does fructose promote fat deposition and obesity more than other nutrients with similar calories?
Does a diet high in FCS promote diabetes or liver, cardiovascular, or kidney disease beyond that caused by excess calories?
Does chronic FCS consumption contribute to the development of insulin resistance in muscle, liver, and adipose tissue? Can consumption of FCS
influence β-cell function and thereby predispose to type II diabetes?
Does chronic FCS consumption contribute to the onset of diabetes?
Does habitual FCS consumption contribute to fatty liver, hypertension, or cardiovascular and kidney diseases?
Is there an effect of FCS on the gut microbiota and intestinal permeability, which play a role in many diseases?
Does a diet high in FCS differently affect some populations?
Are there ethnic or racial populations that are more susceptible to fatty liver disease or other metabolic complications when exposed to a diet high
in FCS?
Are children who ingest high amounts of fructose at increased risk of future metabolic complications?
Are individuals with chronic metabolic disease (obesity, diabetes, cardiovascular disease) more adversely affected by a diet rich in FCS?
Are there maternal diet effects of FCS on offspring with respect to infant growth, learning, and future metabolic disease?
Do chronic over-nutrition and physical activity modulate the effects of a high FCS diet?
Does chronic ingestion of FCS worsen the health effect of a hypercaloric diet?
Does chronic ingestion of FCS worsen the health effect of a sedentary lifestyle? Can physical activity counteract health effects of a diet high in FCS?
If fructose in the diet affects health,
What is the dose relation between dietary fructose and adverse metabolic effects, and to what extent does variation in fructose absorption play a role?
Do the non-sugar components of fruit (vitamins, polyphenols, anthocyanins, fiber) mitigate any adverse effects of dietary fructose?
1 FCS, Fructose-containing sugars.
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still address human health. The experiment can be designed
to answer only 1 such question or a small number of related
questions. Outcomes to be measured can be focused on
biologic pathways, keeping in mind that an outcome can
be statistically significant without being clinically relevant.
Demonstration of both is needed.
Study and control populations
Because mechanistic studies must be highly controlled to
ensure compliance to the protocol and tend to use difﬁcult
complex measurements, they can be expensive and demand-
ing. Depending on the hypothesis to be tested, the study
population can therefore be very narrowly deﬁned and the
number of participants and duration of the study quite
limited.
More than 1 control group may be needed to interpret
the observed effects. For instance, if the study group is obese
insulin-resistant children treated with a low FCS diet to
monitor changes in liver fat, controls may include similar
children on a high FCS diet and obese insulin-sensitive chil-
dren on a low FCS diet. An alternative to multiple control
groups might be a very narrowly deﬁned hypothesis.
Study diets and duration
Baseline diet. An individual’s habitual sugar ingestion be-
fore participating in the study may be an inclusion/exclusion
criterion, because chronic high FCS ingestion can upregu-
late the pathways involved in fructose metabolism and alter
the metabolic response to the intervention diet (14). Diet
may also affect the health outcomes to be measured in
response to an intervention, such as liver fat or rates of de
novo lipogenesis. Alternatively, all participants enrolled in
a short mechanistic study could be treated with a common
lead-in diet for some period of time before the intervention.
If there is no normalizing baseline period, care should be
taken when comparing changes from pre-intervention to
post-intervention among groups.
Defined diets. The intervention diet can be highly artiﬁcial
and controlled, and inpatient studies conducted in clinical
research centers can markedly increase compliance with di-
etary regimens. At 1 extreme would be a multi-week in-
patient stay in which participants consume only prepared
meals that had been made either with pure fructose as a
sweetener or without fructose (i.e., sweetened only with glu-
cose). Deﬁned diets and/or inpatient experiments may be
necessary to investigate whether fructose affects health out-
side of the weight gain caused by a hypercaloric diet, to un-
derstand the protective role of exercise, or when food intake
needs to be carefully monitored to understand whether fruc-
tose causes humans to overeat.
Ad libitum diets. It has been observed that, when sugar-
sweetened beverages are added to the diet, individuals
sometimes, but not always, fail to compensate by reducing
the intake of other food and therefore consume more calo-
ries overall (31–33). However, it remains an open questionTA
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whether there are physiologic mechanisms that mandate
overeating as an appropriate biologic response to sugar con-
sumption. There is also concern that the energy in sugars in-
gested in beverages may be sensed differently than the same
sugars eaten in solid food (63). The effects of sugars on eat-
ing behavior can be studied using a sugar-sweetened supple-
ment added to a diet in which the participants are otherwise
allowed to eat normally (ad libitum diet). Beverage supple-
ments have frequently been used—they are a relatively easy
route to deliver a measured dose of sugar, and they are nat-
uralistic and easy to comply with because individuals are
used to drinking them. Sugar patties or other candy-like
supplements added to an ad libitum low sugar diet could
also be used to investigate the effect of solid vs. liquid sugars
on eating behavior or metabolic pathway intermediates. Al-
ternatively, a study focused on the role of fructose in devel-
opment of NAFLD might be better done using a completely
controlled diet made with pure glucose vs. those made with
FCS.
Special consideration is needed when an ad libitum diet
is used in a mechanistic study. The intervention needs to be
applied for a long enough duration to achieve normalistic
behavior before outcomes are measured, because short-
term ingestive behavior could be altered by, for example,
the knowledge that one is being observed, by unfamiliar
foods in the test diet, and by dose and type of sugar tested.
The palatability of the supplement or intervention diet is
important, because many sensory inputs (taste, smell, texture,
visual cues, other nutrients, etc.) affect the sensation of hun-
ger and eating behavior (and therefore calorie intake).
Control diets. The choice of diet for a control group must
be chosen in light of the speciﬁc mechanistic question to
be addressed, with attention paid to the likelihood of com-
pliance. For highly mechanistic studies, non-sugar nutrients
and palatability should be matched as closely as possible to
the study diet. For studies meant to inform on the inﬂuence
of typical dietary sugars, a diet low in FCS (5% of needed en-
ergy) or one in which all sugars are replaced by complex car-
bohydrates, may be the appropriate control for a high
FCS (25–30% of energy) diet. For studies focused on fruc-
tose metabolic pathways or mechanisms by which fructose
could affect eating behavior, replacement of a fructose-rich
diet with a glucose-rich, fructose-free diet may be more in-
formative. More than 1 control diet may be needed to ensure
that outcomes can be interpreted.
Duration. The study duration need not be long for mecha-
nistic questions. For extremely acute measures (brain imag-
ing, postprandial satiety, metabolic pathways), the duration
may be a few hours. Measureable changes in liver fat or in-
sulin resistance in response to a high sugar hypercaloric diet
may require a single week (64), whereas alterations in weight,
body composition, and eating behavior may take a longer
period of time and different endpoints will require varying
durations to achieve steady state. Pilot studies may be useful
to determine optimum duration.
Disease Outcomes or Health Behavior Studies
Hypotheses
Disease outcomes or health behavior research is designed to
inform health policy and dietary guidelines. Studies tend to
be of long duration and have enough participants that the
results can be generalizable. It can be difﬁcult to control all
the variables, and therefore the outcomes must be of signif-
icant magnitude to be able to overcome large inter-individual
variability.
The hypothesis may be quite broad and encompass a
range of health-related questions (Table 1). Interventions
must be fairly easy to perform and reflective of normal be-
haviors. It is unlikely that highly specific mechanistic ques-
tions can be answered with a very naturalistic intervention
because of the difficulty of monitoring compliance with
the test diet and accurate measurement of calorie intake.
Care should be taken to distinguish between the hypothesis
that ingestion of a particular diet modifies a health outcome,
and the hypothesis that advice to eat a particular diet mod-
ifies the health outcome.
Study and control populations
For dietary health outcomes studies, large diverse groups of
individuals yield the most generalizable data. If a more nar-
rowly deﬁned population, such as children or teenagers, is to
be studied, it should still be representative of a substantial group
TABLE 3 Outcomes measures
Acute measures of fructose metabolism
De novo TG production
Plasma lipids measured over the course of 24 h
Gluconeogenesis, hepatic glucose production
Glucose uptake (muscle, liver, etc.)
Hunger/satiety questionnaire, hunger/satiety hormones, subsequent
food intake
Functional brain activity
Liver ATP transient
Serum uric acid
Postprandial plasma glucose and insulin, leptin, etc.
Flux through metabolic pathways used by and influenced by fructose
Chronic effects of fructose consumption
Weight, BMI
Mood, fatigue, sleep patterns
Daily energy intake
Daily physical activity, spontaneous or intentional
Energy balance
Taste perception, food choice, thirst
Fat mass and distribution, body composition
Protein synthesis
Liver and muscle fat
Liver and kidney function
Bone health
Blood pressure, plasma lipids
Risk factors for chronic diseases
Whole-body and liver insulin resistance
Glucose tolerance, fasting plasma glucose, hemoglobin-A1c, diabetes
onset
Fasting plasma nutrients, metabolites, hormones, adipokines
Inflammation markers
Metabolomic analysis
Gene expression
256 Laughlin et al.
 at UNIVERSITY O
F CALIFO
RNIA DAVIS on April 9, 2015
advances.nutrition.org
D
ow
nloaded from
 
of typical individuals. The choice of a control population is
important. When interventional diets are to be compared,
the control and study groups are likely as closely matched
as possible. For studies comparing groups of individuals, such
as those focused on health disparities, groups should be
matched as closely as possible for remaining traits, such as
age, BMI, gender, and disease state. Researchers should con-
sider that the habitual diets of different ethnic groups may
contain very different amounts and types of sugars, which
may affect study outcomes and present issues for compliance.
There are particular ethical considerations when studying
at-risk populations in long-term protocols. An intervention
designed to improve health outcomes could be used, such as
a diet without sugar-sweetened beverages for 12 mo to see
whether liver fat is reduced or fasting blood sugar is less im-
paired. Such an intervention tests a realistic strategy to im-
prove health in an at-risk population and could inform
health policy. For participants who enter the study with
a low-quality diet, they may beneﬁt from knowledge and
experience at the conclusion of the trial that could help
them achieve better eating habits.
Study diets and duration
For disease outcomes and health behaviors research, the in-
tervention should be as naturalistic as possible to obtain
generalizable data. Sugars in the study and control diets
should be in the form and amounts typically found in the
U.S. diet. It may be too expensive to supply the entire diet
for an extended period of time to a large group of study par-
ticipants, and therefore a design that relies on a dietary sup-
plement or dietary advice may be necessary. Unless the study
design allows for careful monitoring of calorie intake, it may
be impossible to know whether differences in health out-
comes (or even weight or fat mass) among groups are attri-
butable to the metabolism of the sugar in the test diet or
differences in caloric intake. The hypothesis should be
framed in light of these considerations.
The study should be long enough, with a large enough
population, to be able to detect meaningful differences
in health-related biomarkers between study and control
groups. Although it would be unethical to use an interven-
tion to induce real disease endpoints (such as diabetes or a
cardiovascular event), any biomarkers used as outcomes
should be widely accepted as meaningful indicators of dis-
ease risk or progression.
On the importance of compliance
Studies of diet and nutrition are notoriously difﬁcult be-
cause of the complexity of human eating behavior and the
lack of tools to control and measure it accurately, yet the suc-
cess and interpretability of a dietary study, particularly one
focused on biologic mechanisms, is completely dependent
on having the baseline, intervention, and control diets im-
posed as designed. Compliance should be monitored, and,
when no direct measures are available [such as direct obser-
vation of test beverage ingestion or a speciﬁc blood or urine
test for biomarkers included in the test diets (33,65,66)], it
may be prudent to use multiple independent indirect
measures (i.e., return of uneaten test diet, dietary recall ques-
tionnaires, interviews, participant weight). Large studies
may need to be piloted in a small group of individuals to de-
termine whether the intervention can be accomplished and
compliance can be monitored. Realistic projections about
compliance over the long term are essential to achieve ade-
quate statistical power to test the primary hypothesis.
Conclusions
The workshop served to highlight the challenges faced when
designing clinical trials to monitor the health effects of the
current FCS-rich U.S. diets or to identify the mechanisms
underlying the metabolic effects of dietary fructose in hu-
mans. It is clear that, although any one design may answer
only a subset of the important questions surrounding health
and eating behavior, a variety of well-designed, carefully
conducted studies when taken together will provide the ex-
perimental evidence needed for the formulation of dietary
recommendations and health policy. Discussion brought
out the opinion that, although many mechanistic questions
concerning the metabolism of monosaccharide sugars in hu-
mans remain to be addressed experimentally in small highly
controlled studies, health outcomes research meant to in-
form health policy should use large, long-term studies using
combinations of sugars and intake amounts found in the
typical U.S. diet rather than pure fructose or glucose. For
these studies, HFCS and sucrose are likely to be very similar.
The most important outstanding questions include whether
there is an obesogenic role for FCS via effects on eating be-
havior and energy balance, and whether a high FCS diet pro-
motes metabolic changes that lead to type 2 diabetes, liver,
and cardiovascular disease. If so, it is important to determine
the doses of sugar that alter health outcomes and identify
any special populations that are particularly susceptible or
protected from the adverse health effects of a high sugar diet.
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